Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective.

A decision tree model was developed based on the Egyptian clinical practice, and was derived from published sources. This decision analytical model was constructed to assess the costs and consequences associated with aprepitant containing regimen compared with standard therapy for ChemotherapyInduced Nausea and Vomiting (CINV). The clinical parameters were derived from a randomized trial previously published. The utility of the health states was derived using the available published data. Direct medical costs were obtained from the third party payer tariff in Egypt. Deterministic and probabilistic synsitivity analyses were conducted. All costs (in 2014 EGP) and outcomes were discounted at 3.5% annually. Results: